PZ CORMAY S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.608 PLN | -2.56% |
|
-0.33% | +3.40% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 85.36M 21.82M | Sales 2023 | 54.33M 13.89M | Capitalization | 49.51M 12.65M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -1.53M | Net income 2023 | -1M -256K | EV / Sales 2022 | 0.8 x |
| Net cash position 2022 | 6.3M 1.61M | Net Debt 2023 | 3.06M 782K | EV / Sales 2023 | 0.97 x |
| P/E ratio 2022 |
-11.4
x | P/E ratio 2023 |
-25.6
x | Employees | 190 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.56% | ||
| 1 week | -0.33% | ||
| Current month | +3.40% | ||
| 1 month | +3.05% | ||
| 3 months | -5.30% | ||
| 6 months | +6.29% | ||
| Current year | +3.40% |
1 week
0.60
0.63
1 month
0.560.63
Current year
0.560.68
1 year
0.550.81
3 years
0.551.63
5 years
0.553.36
10 years
0.557.59
| Managers | Title | Age | Since |
|---|---|---|---|
Flavio Finotello
CEO | Chief Executive Officer | - | 17-08-31 |
Marcin Sieczek
BRD | Director/Board Member | - | 23-01-02 |
| Corporate Officer/Principal | - | 14-08-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tomasz Markowski
CHM | Chairman | - | 16-06-29 |
Bartosz Marczuk
BRD | Director/Board Member | 52 | - |
Marcin Sieczek
BRD | Director/Board Member | - | 23-01-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 0.608 | -2.56% | 4 842 |
| 24-05-20 | 0.624 | +0.65% | 15,247 |
| 24-05-17 | 0.62 | -1.59% | 5,453 |
| 24-05-16 | 0.63 | +0.32% | 33,562 |
| 24-05-15 | 0.628 | +2.95% | 62,740 |
Delayed Quote Warsaw S.E., May 21, 2024 at 07:26 am EDT
More quotes
PZ Cormay SA is a Polish-based producer and wholesaler of diagnostic reagents and a distributor of the laboratory equipment. The Company is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. It offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.40% | 13.43M | |
| -6.26% | 12.23B | |
| -3.86% | 8.17B | |
| +5.88% | 5.78B | |
| +33.66% | 5.74B | |
| -7.35% | 4.24B | |
| -55.63% | 2.97B | |
| +13.62% | 2.73B | |
| -4.16% | 2.38B | |
| +30.67% | 2.26B |
- Stock Market
- Equities
- CRM Stock
